The impact of psychiatric and extraintestinal comorbidity on quality of life and bowel symptom burden in functional GI disorders

Neurogastroenterology and Motility

Volumn 26, Issue 9, 2014, Pages 1323-1332

  Vu, J ^a   Kushnir, V ^b   Cassell, B ^b   Gyawali, C P ^b   Sayuk, G S ^a,b  

^a SAINT LOUIS UNIVERSITY   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Functional dyspepsia; Irritable bowel syndrome; Psychosomatic medicine; Quality of life

Indexed keywords

ADULT; ANXIETY; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DEPRESSION; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE CLASSIFICATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; DYSPEPSIA; EXTRAINTESTINAL FUNCTIONAL DISORDER; FEMALE; GASTROINTESTINAL SYMPTOM; GENDER; HUMAN; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MOOD DISORDER; PATIENT HEALTH QUESTIONNAIRE; PREDICTIVE VALUE; PRIORITY JOURNAL; QUALITY OF LIFE; SHORT FORM 36; SOMATIZATION;

EID: 84904845564     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/nmo.12396     Document Type: Article

References (41)

1. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006; 130: 1480-91.
2. Chang L. Review article: epidemiology and quality of life in functional gastrointestinal disorders. Aliment Pharmacol Ther 2004; 20: 31-9.
3. Nyrop KA, Palsson OS, Levy RL, Korff MV, Feld AD, Turner MJ, Whitehead WE. Costs of health care for irritable bowel syndrome, chronic constipation, functional diarrhoea and functional abdominal pain. Aliment Pharmacol Ther 2007; 26: 237-48.
4. Hussain KB, Fontana RJ, Moyer CA, Su GL, Sneed-Pee N, Lok AS. Comorbid illness is an important determinant of health-related quality of life in patients with chronic hepatitis C. Am J Gastroenterol 2001; 96: 2737-44.
5. Borgaonkar MR, Townson G, Donnelly M, Irvine EJ. Providing disease-related information worsens health-related quality of life in inflammatory bowel disease. Inflamm Bowel Dis 2002; 8: 264-9.
6. Naliboff BD, Kim SE, Bolus R, Bernstein CN, Mayer EA, Chang L. Gastrointestinal and psychological mediators of health-related quality of life in IBS and IBD: a structural equation modeling analysis. Am J Gastroenterol 2012; 107: 451-9.
7. Sayuk GS, Elwing JE, Lustman PJ, Clouse RE. High somatic symptom burdens and functional gastrointestinal disorders. Clin Gastroenterol Hepatol 2007; 5: 556-62.
8. Whitehead WE, Palsson O, Jones KR. Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications? Gastroenterology 2002; 122: 1140-56.
9. Walker EA, Gelfand AN, Gelfand MD, Katon WJ. Psychiatric diagnoses, sexual and physical victimization, and disability in patients with irritable bowel syndrome or inflammatory bowel disease. Psychol Med 1995; 25: 1259-67.
10. Lydiard RB, Fossey MD, Marsh W, Ballenger JC. Prevalence of psychiatric disorders in patients with irritable bowel syndrome. Psychosomatics 1993; 34: 229-34.
11. Sykes MA, Blanchard EB, Lackner J, Keefer L, Krasner S. Psychopathology in irritable bowel syndrome: support for a psychophysiological model. J Behav Med 2003; 26: 361-72.
12. Bennett EJ, Piesse C, Palmer K, Badcock CA, Tennant CC, Kellow JE. Functional gastrointestinal disorders: psychological, social, and somatic features. Gut 1998; 42: 414-20.
13. Drossman DACE, Delvaux M, Spiller RC, Talley NJ, Thompson WG, Whitehead W, eds. Rome III: The Functional Gastrointestinal Disorders. McLean, VA: Degnon Associates Inc, 2006.
14. Miller AR, North CS, Clouse RE, Wetzel RD, Spitznagel EL, Alpers DH. The association of irritable bowel syndrome and somatization disorder. Ann Clin Psychiatry 2001; 13: 25-30.
15. Riedl A, Schmidtmann M, Stengel A, Goebel M, Wisser AS, Klapp BF, Monnikes H. Somatic comorbidities of irritable bowel syndrome: a systematic analysis. J Psychosom Res 2008; 64: 573-82.
16. Spiller R, Aziz Q, Creed F, Emmanuel A, Houghton L, Hungin P, Jones R, Kumar D et al. Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut 2007; 56: 1770-98.
17. Elsenbruch S. Abdominal pain in Irritable Bowel Syndrome: a review of putative psychological, neural and neuro-immune mechanisms. Brain Behav Immun 2011; 25: 386-94.
18. Brandt LJ, Chey WD, Foxx-Orenstein AE, Schiller LR, Schoenfeld PS, Spiegel BM, Talley NJ, Quigley EM. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol 2009; 104(Suppl. 1): S1-35.
19. Winslow E, Clouse R, Desai K, Frisella P, Gunsberger T, Soper N, Klingensmith M. Influence of spastic motor disorders of the esophageal body on outcomes from laparoscopic antireflux surgery. Surg Endosc 2003; 17: 738-45.
20. Kushnir V, Cassell B, Gyawali C, Newberry R, Kibe P, Nix B, Sabzpoushan A, Kanuri N et al. Genetic variation in the beta-2 adrenergic receptor (ADRB2) predicts functional gastrointestinal diagnoses and poorer health-related quality of life. Aliment Pharmacol Ther 2013; 38: 313-23.
21. Wiklund IK, Fullerton S, Hawkey CJ, Jones RH, Longstreth GF, Mayer EA, Peacock RA, Wilson IK et al. An irritable bowel syndrome-specific symptom questionnaire: development and validation. Scand J Gastroenterol 2003; 38: 947-54.
22. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961; 4: 561.
23. Steer RA, Ball R, Ranieri WF, Beck AT. Dimensions of the Beck Depression Inventory-II in clinically depressed outpatients. J Clin Psychol 1999; 55: 117-28.
24. Kroenke K, Spitzer RL, Williams JB. The PHQ-15: validity of a new measure for evaluating the severity of somatic symptoms. Psychosom Med 2002; 64: 258-66.
25. McHorney CA, Ware JE Jr, Lu JF, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care 1994; 32: 40-66.
26. Baron RM, Kenny DA. The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. J Pers Soc Psychol 1986; 51: 1173-82.
27. Whitehead WE, Burnett CK, Cook EW 3rd, Taub E. Impact of irritable bowel syndrome on quality of life. Dig Dis Sci 1996; 41: 2248-53.
28. El-Serag HB. Impact of irritable bowel syndrome: prevalence and effect on health-related quality of life. Rev Gastroenterol Disord 2003; 3(Suppl. 2): S3-11.
29. Gralnek IM, Hays RD, Kilbourne A, Naliboff B, Mayer EA. The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology 2000; 119: 654-60.
30. Spiegel BM, Kanwal F, Naliboff B, Mayer E. The impact of somatization on the use of gastrointestinal health-care resources in patients with irritable bowel syndrome. Am J Gastroenterol 2005; 100: 2262-73.
31. Sayuk GS, Elwing JE, Lustman PJ, Clouse RE. Predictors of premature antidepressant discontinuation in functional gastrointestinal disorders. Psychosom Med 2007; 69: 173-81.
32. Spiegel BM, Gralnek IM, Bolus R et al. Clinical determinants of health-related quality of life in patients with irritable bowel syndrome. Arch Intern Med 2004; 164: 1773-80.
33. Paulhus DL. Measurement and control of response bias. In: Robinson JP, Shaver PR, Wirghtsman LS, eds. Measures of Personality and Social Psychological Attitudes. San Diego, CA: Academic Press Inc, 1991: 17-59.
34. Mayer EA, Naliboff BD, Craig AD. Neuroimaging of the brain-gut axis: from basic understanding to treatment of functional GI disorders. Gastroenterology 2006; 131: 1925-42.
35. Tracey I, Mantyh PW. The cerebral signature for pain perception and its modulation. Neuron 2007; 55: 377-91.
36. Van Oudenhove L, Aziz Q. The role of psychosocial factors and psychiatric disorders in functional dyspepsia. Nat Rev Gastroenterol Hepatol 2013; 10: 158-67.
37. Mayer EA, Berman S, Suyenobu B, Labus J, Mandelkern MA, Naliboff BD, Chang L. Differences in brain responses to visceral pain between patients with irritable bowel syndrome and ulcerative colitis. Pain 2005; 115: 398-409.
38. Labus JS, Naliboff BD, Berman SM, Suyenobu B, Vianna EP, Tillisch K, Mayer EA. Brain networks underlying perceptual habituation to repeated aversive visceral stimuli in patients with irritable bowel syndrome. Neuroimage 2009; 47: 952-60.
39. Hahn BA, Kirchdoerfer LJ, Fullerton S, Mayer E. Patient-perceived severity of irritable bowel syndrome in relation to symptoms, health resource utilization and quality of life. Aliment Pharmacol Ther 1997; 11: 553-9.
40. Corsetti M, Tack J. FDA and EMA end points: which outcome end points should we use in clinical trials in patients with irritable bowel syndrome? Neurogastroenterol Motil 2013; 25: 453-7.
41. Sayuk GS. Linaclotide: promising IBS-C efficacy in an era of provisional study endpoints. Am J Gastroenterol 2012; 107: 1726-9.